PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.03
Negative P/E while Biotechnology median is -3.14. Seth Klarman would scrutinize path to profitability versus peers.
4088.78
P/S exceeding 1.5x Biotechnology median of 5.10. Jim Chanos would check for potential multiple compression risks.
2.58
P/B 1.25-1.5x Biotechnology median of 2.03. Guy Spier would scrutinize if premium reflects better asset utilization.
-31.79
Negative FCF while Biotechnology median P/FCF is -16.07. Seth Klarman would investigate cash flow improvement potential.
-32.20
Negative operating cash flow while Biotechnology median P/OCF is -16.17. Seth Klarman would investigate operational improvement potential.
2.58
Fair value ratio 1.25-1.5x Biotechnology median of 2.03. Guy Spier would scrutinize if premium reflects durable advantages.
-4.97%
Negative earnings while Biotechnology median yield is -4.72%. Seth Klarman would investigate path to profitability.
-3.15%
Negative FCF while Biotechnology median yield is -3.98%. Seth Klarman would investigate cash flow improvement potential.